Table 4.
Serum and urinary FGF23, IGFBP-7 and CysC levels grouped according to AKI status
| Biomarker | Non-AKI | Mild AKI | Severe AKI | P |
|---|---|---|---|---|
| (n = 123) | (n = 10) | (n = 11) | ||
| sFGF23, pg/mL | 79.33 [49.88–115.84] | 59.97 [50.25–81.57] | 92.33 [49.98–107.50] | 0.372 |
| sIGFBP-7, ng/mL | 107.92 [87.47–125.02] | 108.17 [83.65–135.71] | 125.26 [103.07–148.35] | 0.255 |
| sCysC, mg/L | 0.60 [0.47–0.78] | 0.73 [0.54–0.96] | 1.10 [1.06–1.72]*# | < 0.001 |
| uFGF23, pg/mg uCr | 74.40 [39.20–225.8] | 47.14 [28.82–130.6] | 172.93 [114.37–448.25]*# | 0.033 |
| uIGFBP-7, ng/mg uCr | 291.57 [135.60–539.04] | 244.33 [87.51–478.73] | 653.50 [301.94–2072.06]*# | 0.005 |
| uCysC, ng/mg uCr | 183.17 [94.62–494.96] | 122.38 [80.27–332.97] | 6559.79 [1224.42–30,414.64]*# | < 0.001 |
Values are median [interquartile range]
AKI network stage 1 was defined as mild AKI, and AKIN stages 2 and 3 were defined as severe AKI
*P < 0.05, compared with non-AKI; #P < 0.05, compared with mild AKI